Top

Irish Journal of Medical Science (1971 -)

Published in:

01-08-2020 | Multiple Myeloma | Original Article

Knockdown of long non-coding RNA plasmacytoma variant translocation 1 inhibits cell proliferation while promotes cell apoptosis via regulating miR-486-mediated CDK4 and BCAS2 in multiple myeloma

Authors: Man Zhang, Xuliang Zhao, Xinan Cai, Pengcheng Wang, Min Yu, Zhuojun Wei

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2020

Abstract

Aims

This study aimed to investigate the effect of long non-coding RNA-plasmacytoma variant translocation 1 (lnc-Pvt1) knockdown on regulating cell proliferation and apoptosis, and to explore its molecular mechanism in multiple myeloma (MM).

Methods

Lnc-Pvt1 expression was detected in MM cell lines (NCI-H929, U-266, LP-1 and RPMI-8226 cell lines) and human normal plasma cells. In U-266 cells and LP-1 cells, control shRNA and lnc-Pvt1 shRNA plasmids were transferred. Rescue experiments were further performed by transfection of lnc-Pvt1 shRNA alone and lnc-Pvt1 shRNA and miR-486 shRNA plasmids. Cells proliferation, apoptosis, RNA expression, and protein expression were determined by cell counting kit-8, annexin V-FITC-propidium iodide, quantitative polymerase chain reaction, and Western blot assays, respectively.

Results

Lnc-Pvt1 expression was increased in MM cell lines (NCI-H929, U-266 and LP-1 cell lines) compared with human normal plasma cells. In U-266 cells, lnc-Pvt1 shRNA suppressed cell proliferation while enhanced cell apoptosis compared with control shRNA. Also, lnc-Pvt1 shRNA increased miR-486 expression compared with control shRNA. Further rescue experiment revealed that miR-486 shRNA did not change lnc-Pvt1 level, but increased CDK4 and BCAS2 expressions in lnc-Pvt1 knockdown–treated cells. In addition, miR-486 shRNA promoted cell proliferation while inhibited cell apoptosis in lnc-Pvt1 knockdown–treated cells. These results were further validated in LP-1 cells.

Conclusions

Lnc-Pvt1 knockdown inhibits cell proliferation and induces cell apoptosis through potentially regulating miR-486-mediated CDK4 and BCAS2 in MM.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252–262. https://doi.org/10.1038/leu.2017.329 CrossRefPubMed

Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I (2018) Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia 32(7):1500–1514. https://doi.org/10.1038/s41375-018-0061-9 CrossRefPubMedPubMedCentral

Saxe D, Seo EJ, Bergeron MB, Han JY (2019) Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol 41(1):5–14. https://doi.org/10.1111/ijlh.12882 CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Holstein SA, Suman VJ, McCarthy PL (2019) Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep 14(1):31–38. https://doi.org/10.1007/s11899-019-0495-9 CrossRefPubMed

Albagoush S, Azevedo A (2018) Cancer. Multiple myeloma. in StatPearls Publishing, Treasure Island, FL

Engreitz JM, Ollikainen N, Guttman M (2016) Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol 17(12):756–770. https://doi.org/10.1038/nrm.2016.126 CrossRefPubMed

Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17(1):47–62. https://doi.org/10.1038/nrg.2015.10 CrossRefPubMed

Wahlestedt C (2013) Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov 12(6):433–446. https://doi.org/10.1038/nrd4018 CrossRefPubMed

10.

Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15(1):7–21. https://doi.org/10.1038/nrg3606 CrossRefPubMed

11.

Wang L, Wang R, Ye Z, Wang Y, Li X, Chen W, Zhang M, Cai C (2018) PVT1 affects EMT and cell proliferation and migration via regulating p21 in triple-negative breast cancer cells cultured with mature adipogenic medium. Acta Biochim Biophys Sin Shanghai 50(12):1211–1218. https://doi.org/10.1093/abbs/gmy129 CrossRefPubMed

12.

Zou MF, Ling J, Wu QY, Zhang CX (2018) Long non-coding RNA PVT1 functions as an oncogene in ovarian cancer via upregulating SOX2. Eur Rev Med Pharmacol Sci 22(21):7183–7188. https://doi.org/10.26355/eurrev_201811_16251 CrossRefPubMed

13.

Tian Z, Cao S, Li C, Xu M, Wei H, Yang H, Sun Q, Ren Q, Zhang L (2019) LncRNA PVT1 regulates growth, migration, and invasion of bladder cancer by miR-31/ CDK1. J Cell Physiol 234(4):4799–4811. https://doi.org/10.1002/jcp.27279 CrossRefPubMed

14.

Salehi M, Sharifi M (2018) Induction of apoptosis and necrosis in human acute erythroleukemia cells by inhibition of long non-coding RNA PVT1. Mol Biol Res Commun 7(2):89–96. https://doi.org/10.22099/mbrc.2018.29081.1316 CrossRefPubMedPubMedCentral

15.

Izadifard M, Pashaiefar H, Yaghmaie M, Montazeri M, Sadraie M, Momeny M, Jalili M, Ahmadvand M, Ghaffari SH, Mohammadi S, Alimoghaddam K, Ghavamzadeh A (2018) Expression analysis of PVT1, CCDC26, and CCAT1 long noncoding RNAs in acute myeloid leukemia patients. Genet Test Mol Biomarkers 22(10):593–598. https://doi.org/10.1089/gtmb.2018.0143 CrossRefPubMed

16.

Guan Z, Tan J, Gao W, Li X, Yang Y, Li X, Li Y, Wang Q (2018) Circular RNA hsa_circ_0016788 regulates hepatocellular carcinoma tumorigenesis through miR-486/CDK4 pathway. J Cell Physiol 234(1):500–508. https://doi.org/10.1002/jcp.26612 CrossRefPubMed

17.

Lang B, Zhao S (2018) miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2. Oncol Rep 39(1):71–80. https://doi.org/10.3892/or.2017.6064 CrossRefPubMed

18.

Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ, Lu SD, He YY, Wang P, Sun QL, Jin YX, Ma ZL (2016) Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer. Oncotarget 7(23):34011–34021. https://doi.org/10.18632/oncotarget.8514 CrossRefPubMedPubMedCentral

19.

Colombo T, Farina L, Macino G, Paci P (2015) PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int 2015:304208. https://doi.org/10.1155/2015/304208 CrossRefPubMedPubMedCentral

20.

Xiao M, Feng Y, Liu C, Zhang Z (2018) Prognostic values of long noncoding RNA PVT1 in various carcinomas: an updated systematic review and meta-analysis. Cell Prolif 51(6):e12519. https://doi.org/10.1111/cpr.12519 CrossRefPubMedPubMedCentral

21.

Chen X, Yang Y, Cao Y, Wu C, Wu S, Su Z, Jin H, Wang D, Zhang G, Fan W, Lin J, Zeng Y, Hu D (2018) lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis. Cancer Manag Res 10:2711–2727. https://doi.org/10.2147/CMAR.S166260 CrossRefPubMedPubMedCentral

22.

Zhang R, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W, Liu Y (2018) Long noncoding RNA plasmacytoma variant translocation 1 (PVT1) promotes colon cancer progression via endogenous sponging miR-26b. Med Sci Monit 24:8685–8692. https://doi.org/10.12659/MSM.910955 CrossRefPubMedPubMedCentral

23.

Yu Y, Zhang M, Liu J, Xu B, Yang J, Wang N, Yan S, Wang F, He X, Ji G, Li Q, Miao L (2018) Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in Cholangiocarcinoma. Mol Ther Nucleic Acids 13:503–513. https://doi.org/10.1016/j.omtn.2018.10.001 CrossRefPubMedPubMedCentral

24.

Zhang Y, Yang G, Luo Y (2019) Long non-coding RNA PVT1 promotes glioma cell proliferation and invasion by targeting miR-200a. Exp Ther Med 17(2):1337–1345. https://doi.org/10.3892/etm.2018.7083 CrossRefPubMed

25.

Hua J, Ding T, Yang L (2016) Dysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma disease. Onco Targets Ther 9:6573–6579. https://doi.org/10.2147/OTT.S105945 CrossRefPubMedPubMedCentral

26.

Jiang Y, Chang H, Chen G (2018) Effects of microRNA-20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway. Oncol Lett 15(6):10001–10007. https://doi.org/10.3892/ol.2018.8555 CrossRefPubMedPubMedCentral

27.

Huang G, Liu X, Zhao X, Zhao J, Hao J, Ren J, Chen Y (2019) MiR-9 promotes multiple myeloma progression by regulating TRIM56/NF-kappaB pathway. Cell Biol Int. https://doi.org/10.1002/cbin.11104

28.

Liu H, Ni Z, Shi L, Ma L, Zhao J (2019) MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1. Mol Cell Probes 44:37–43. https://doi.org/10.1016/j.mcp.2019.02.001 CrossRefPubMed

29.

Wang LS, Li L, Li L, Chu S, Shiang KD, Li M, Sun HY, Xu J, Xiao FJ, Sun G, Rossi JJ, Ho Y, Bhatia R (2015) MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood 125(8):1302–1313. https://doi.org/10.1182/blood-2014-06-581926 CrossRefPubMedPubMedCentral

30.

Iriyama N, Hino H, Moriya S, Hiramoto M, Hatta Y, Takei M, Miyazawa K (2018) The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells. Leuk Lymphoma 59(6):1439–1450. https://doi.org/10.1080/10428194.2017.1376741 CrossRefPubMed

31.

Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S (2016) Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma. Cancer Res 76(5):1225–1236. https://doi.org/10.1158/0008-5472.CAN-15-2934 CrossRefPubMedPubMedCentral

32.

Kuo PC, Tsao YP, Chang HW, Chen PH, Huang CW, Lin ST, Weng YT, Tsai TC, Shieh SY, Chen SL (2009) Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res 69(23):8877–8885. https://doi.org/10.1158/0008-5472.CAN-09-2023 CrossRefPubMed

Title: Knockdown of long non-coding RNA plasmacytoma variant translocation 1 inhibits cell proliferation while promotes cell apoptosis via regulating miR-486-mediated CDK4 and BCAS2 in multiple myeloma
Authors: Man Zhang
Xuliang Zhao
Xinan Cai
Pengcheng Wang
Min Yu
Zhuojun Wei
Publication date: 01-08-2020
Publisher: Springer London
Keyword: Multiple Myeloma
Published in: Irish Journal of Medical Science (1971 -) / Issue 3/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-019-02165-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Sponsorship, advertising and alcohol control in Ireland: the importance of both premises and products in regulating intoxigenic environments

Unknown breastfeeding rates among Traveller women in Ireland: a systems failure to collect, record and report

The role of primary care in management of rare diseases in Ireland

Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit

Effects of intravenous and mask induction on post-operative emergence delirium in pediatric patients undergoing tonsillectomy with or without adenoidectomy

Gender differences in the revascularization rates and in-hospital outcomes in hospitalizations with ST segment elevation myocardial infarction

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials